Dr Chris Baldwin CCO of Exopharm presents at Bio CEO & Investor Digital Conference
The company has had several rounds of questions and interactions with the FDA and believes it is now in the final round of questions from the FDA ahead of marketing approval.
Incannex appoints EAS Advisors LLC to facilitate introductions to US banks and institutions with the intention to list on a US main market
The predominant purpose of the consulting arrangement is for EAS to facilitate introductions to US banks and institutions with the aim of dual listing IHL securities on a US main market, such as [...]
• New collaboration with the Walter Reed Army Institute of Research (WRAIR) and UNSW Sydney (UNSW) • World-leading scientific teams to evaluate and advance Nyrada’s lead preclinical [...]